First approval for new tuberculosis drugs paves the way for better combinations of new and old agents.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
Communications Biology Open Access 24 February 2022
-
Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis
Nature Communications Open Access 30 November 2020
-
IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis
Scientific Reports Open Access 28 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Tuberculosis success. Nat Rev Drug Discov 12, 175–176 (2013). https://doi.org/10.1038/nrd3957
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3957
This article is cited by
-
Asymmetric synthesis of bedaquiline based on bimetallic activation and non-covalent interaction promotion strategies
Science China Chemistry (2022)
-
An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
Communications Biology (2022)
-
Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis
Nature Communications (2020)
-
IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis
Scientific Reports (2018)
-
The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd
Scientific Reports (2018)